Edwyn
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | $14,351 | $17,108 | $18,449 | $20,498 | $22,595 |
| Gross Profit | $9,057 | $10,968 | $11,578 | $13,058 | $14,440 |
| Operating Income | $2,223 | $2,584 | $2,841 | $3,888 | $3,689 |
| Net Income | $1,599 | $1,994 | $2,358 | $3,165 | $2,993 |
Over the past five years, Stryker Corporation has demonstrated steady revenue and gross profit expansion. Revenue increased from USD 14,351 million in 2020 to USD 22,595 million in 2024, reflecting a cumulative growth of approximately 57 percent. Gross profit followed a similar upward trend, rising from USD 9,057 million to USD 14,440 million over the same period, which indicates that the company has been able to efficiently convert sales into profit despite inflationary pressures and competitive dynamics in the medical technology industry. Notably, while year-over-year increases were mostly moderate—with revenue growth generally under 20 percent—there is consistent growth in both top-line and gross profitability, underscoring a robust operational framework. However, operating income and net income showed mixed performance during this period. Operating income increased from USD 2,223 million in 2020 to a peak of USD 3,888 million in 2023, before experiencing a decline to USD 3,689 million in 2024, and a similar pattern is observed in net income, which peaked at USD 3,165 million in 2023 before falling to USD 2,993 million in 2024. These declines, while not exceeding a 20 percent drop year-over-year, may be indicative of rising operational expenses or changes in cost structure, warranting further review. Overall, Stryker’s financial health appears strong, with solid revenue and profit growth over the long term, although the slight contraction in operating and net income in the most recent year suggests a need for continued vigilance in cost management and operational efficiency.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.